Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Assets Average (2017 - 2025)

Aclaris Therapeutics has reported Assets Average over the past 9 years, most recently at $168.0 million for Q4 2025.

  • Quarterly results put Assets Average at $168.0 million for Q4 2025, down 16.57% from a year ago — trailing twelve months through Dec 2025 was $168.0 million (down 16.57% YoY), and the annual figure for FY2025 was $190.4 million, down 8.84%.
  • Assets Average for Q4 2025 was $168.0 million at Aclaris Therapeutics, down from $182.3 million in the prior quarter.
  • Over the last five years, Assets Average for ACRS hit a ceiling of $275.8 million in Q3 2021 and a floor of $116.1 million in Q1 2021.
  • Median Assets Average over the past 5 years was $217.0 million (2021), compared with a mean of $214.4 million.
  • Biggest five-year swings in Assets Average: soared 260.73% in 2021 and later dropped 27.98% in 2024.
  • Aclaris Therapeutics' Assets Average stood at $257.4 million in 2021, then increased by 1.46% to $261.1 million in 2022, then dropped by 20.39% to $207.9 million in 2023, then fell by 3.14% to $201.4 million in 2024, then decreased by 16.57% to $168.0 million in 2025.
  • The last three reported values for Assets Average were $168.0 million (Q4 2025), $182.3 million (Q3 2025), and $193.6 million (Q2 2025) per Business Quant data.